RVAC Medicines Pte. Ltd., a Singapore-based messenger RNA (mRNA) technology platform company incubated by CBC Group, announced on Wednesday that it has dosed a participant in a phase one, first-in-human study assessing the company's mRNA-based COVID-19 vaccine candidate, RVM-V001.
The Phase 1 study, an open-label, dose escalation study, is intended to assess the safety and immunogenicity of RVM-V001 in around 54 healthy adults in Australia.
This study is part of a series of clinical trials intended to assess RVAC's range of COVID-19 vaccine candidates that include one against the ancestral strain, one against the Omicron strain and a bivalent vaccine candidate with components of both ancestral and Omicron strains.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients